ILMN · Illumina Inc
Price
Snapshot
50 fields · last close| Market Cap | $39.64B |
| P/E | 48.05 |
| Float | 150.9M |
| Beta | 1.43 |
| Volatility | 35.8% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 67.1 |
| Price | 262.58 |
| Change | +0.02% |
| Prev Close | 262.54 |
| Open | 267.49 |
| Day Low | 259.25 |
| Day High | 272.00 |
| Avg Vol | 3 |
| Avg $ Vol | $728.7M |
| 52W High | 309.35 |
| 52W Low | 93.50 |
| 52W Pos | 78.3% |
| From High | −15.12% |
| From Low | +180.83% |
| Max DD 1Y | −25.66% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −2.20% |
| SMA 50 | +12.25% |
| SMA 200 | +54.77% |
| RSI (14) | 53.1 |
| Vol 30D | 56.2% |
| Vol 90D | 47.6% |
| 1Y Range | 94–309 |
| Daily bars | 536 |
| Perf Week | −5.62% |
| Perf Month | +7.08% |
| Perf Quarter | +42.16% |
| Perf Half Y | +95.20% |
| Perf Year | +182.30% |
| Perf YTD | +95.44% |
| Prev Day | +0.02% |
| Clavix | B- |
| Debt / Eq | 0.31 |
| Curr Ratio | 2.08 |
| Int Cover | 11.0× |
| FCF Margin | 21.4% |
| Rev Growth | −0.7% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 15 / 19 |
Clavix risk grade
regraded every trading dayILMN grades B-, 67.1 of 100. Steadiest on Sector Resilience (71), most exposed on Price Stability (50, mixed). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 15 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| ILMN | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.43 | 1.18 |
| Volatilityannualized | 35.8% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −25.7% | — |
| Typical daily movemedian absolute daily change | 1.81% | — |
| Days beyond ±3%of the last 252 sessions | 57 (23%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ILMN | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.43 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ILMN | |
|---|---|
| 1 week | −5.6% |
| 1 month | +7.1% |
| Year to date | +95.4% |
| 1 year | +182.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ILMN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 20 Aug |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 6 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| ILMN | |
|---|---|
| Revenue growthyear over year | −0.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openIllumina announced the launch of BioInsight, a new unified software platform that combines its analysis software, AI tools, and curated data resources into one environment for analyzing genomic and multiomics datasets, ahead of the ASHG meeting in Montreal.
On October 14, 2026, Illumina launched BioInsight Platform, its first unified software environment that brings its analysis tools, AI features, and curated biological data into one place to help researchers work with genomic and multiomic data. The launch includes an updated version of DRAGEN, Illumina's secondary analysis (meaning, the step that turns raw DNA sequencing output into readable genetic data) software, now available across both cloud and standard computing setups.
Illumina launched BioInsight, its first unified software environment that brings together the company's analysis applications, AI tools, and curated data resources to help researchers analyze genomic and multiomic data without juggling separate informatics tools.
Illumina has set up a program that lets it borrow up to $1 billion in the short term by issuing unsecured IOUs called commercial paper, to be used for general business needs. As of the filing, it had not actually borrowed anything under the program.
In October 2026, Illumina announced SpliceAI2, a new AI model that helps researchers better detect disease-relevant splice variants (small genetic differences that affect how genes are read and can drive disease) across rare disease, hereditary cancer, and drug discovery applications. The article notes it improves on earlier detection tools and could support higher-value research and clinical workflows.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| WAT | Waters Corp | B+ | $43.78B | 263.53 | 1.16 | Compare |
| IQV | IQVIA Holdings Inc | B | $43.93B | 31.95 | 1.18 | Compare |
| MTD | Mettler-toledo International Inc | B+ | $32.51B | 35.89 | 1.19 | Compare |
| A | Agilent Technologies Inc | B | $48.77B | 33.86 | 1.25 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 49.78 | 1.15 | Compare |
| MEDP | Medpace Holdings Inc | B | $17.26B | 35.12 | 1.11 | Compare |
| RVTY | Revvity Inc | B | $17.03B | 71.70 | 1.09 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.33B | — | 1.37 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.